You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

June 15, 2020

Thailand Takes Steps to Ensure Availability of High-Demand Medical Supplies

Informed Counsel

Dealing with the COVID-19 pandemic has taken top priority for almost every country in the world. In Thailand, even though the strength of the country’s health security measures has been ranked sixth-best globally, COVID-19 hit hard, and the country has only just begun to detail with the effects of the outbreak.    

In the early stages of the outbreak in January 2020, only passengers who had visited mainland China were subject to close monitoring by communicable disease control officers. By late February, South Korea had become another epicenter of the outbreak, and many Thai nationals who had been working there chose to return home to Thailand to avoid COVID-19 infection. Thailand’s Ministry of Public Health (MOPH) was concerned that the local outbreak would become more widespread as a result of these returnees infecting others (if indeed they were infected). While this risk now seems to have been successfully handled, the virus continues to rage in various countries in Asia and around the world.   

These circumstances preceded the MOPH designating COVID-19 as a “dangerous communicable disease” under the Communicable Disease Act B.E. 2558 (2015). While incoming international travel was effectively sealed off relatively early on, the few remaining incoming travelers have been subject to certain conditions such as quarantine and special monitoring.   

Communicable disease control officers are empowered to require suspected persons to be diagnosed and quarantined. Under the current rules, all COVID-19 patients and suspected COVID-19 patients—defined as having a fever higher than 37.5 degrees Celsius and any other symptom associated with COVID-19, such as coughing, a runny nose, a sore throat, or shortness of breath—are brought to a medical facility specified by the MOPH for diagnosis, treatment, isolation, and quarantine, as necessary. People returning from high-risk areas but not showing any symptoms have been subject to a mandatory 14-day quarantine and have had to adhere to strict health-related follow-up exams.    

Apart from the quarantine measures, people have been advised to strictly practice good personal hygiene throughout the course of the outbreak. Unsurprisingly, alcohol-based hand sanitizers and face masks have faced severe shortages in Thailand. The MOPH has been involved in the supply of these high-demand items by relaxing some regulations on their importation and production. However, these moves alone are not considered sufficient. The Department of Internal Trade of the Ministry of Commerce has also stepped in to control the supply and set up the maximum allowable purchase price of face masks. Other regulations related to these products have been modified to counteract shortages—examples include reclassification of alcohol-based hand sanitizers, implementation of fast-track pathways for the domestic production of alcohol-based hand sanitizers, declaration of alcohol-based hand sanitizers and disposable medical masks as controlled goods, and so on. Regulations such as these will likely continue to change periodically, so healthcare entrepreneurs should check frequently that they are compliant with the latest updates.

Thailand’s Updated Regulations on Alcohol-Based Hand Sanitizers and Disposable Medical Masks   

The Cosmetics Act B.E. 2558 (2015) and the Medical Device Act B.E. 2551 (2008), as amended, provide the regulatory framework for the trading and post-marketing surveillance of both alcohol-based hand sanitizers and face masks in Thailand. In 2019, the MOPH reclassified alcohol-based hand sanitizers as medical devices (instead of their previous categorization as cosmetics), with the reclassification to enter into force on March 11, 2020. However, the COVID-19 outbreak intervened, causing a shortage of alcohol-based sanitizers. The MOPH acted to ease this shortage by canceling the reclassification of alcohol-based hand sanitizers because the more stringent controls applied to medical devices would cause unnecessary delays. Alcohol-based hand sanitizers will therefore continue to be classified as cosmetics for the foreseeable future.    

For new registrations of alcohol-based hand sanitizers, it was announced that only products containing alcohol concentrations greater than 65% w/w would be allowed to be registered (through notification and approval) as controlled cosmetics. The notification certificate is valid for three years and is renewable. The Thai Food and Drug Administration (FDA) has also relaxed regulations to allow pharmaceutical manufacturers, traditional drug manufacturers, and medical device manufacturers located in Thailand to produce and sell alcohol-based hand sanitizer without having to first obtain a cosmetics manufacturing license. In other words, after registering its product with the FDA, the manufacturer can bring it to market.    

The shortage of disposable masks is much more acute. Hospitals have run out of their supply due to high public demand, low production scale, and hoarding. Some people have seen this as an opportunity to earn extra income by making and selling homemade masks as an alternative to commercial face masks. These reusable homemade masks are not classified as medical devices and cannot be claimed to be personal protective equipment against the coronavirus. Only disposable medical masks are regulated; they are classified as low-risk medical devices. Imported masks require product registration with the Thai FDA. For domestically manufactured masks, although product registration is not required, the domestic manufacturer is still required to register the establishment as a medical device manufacturer with the FDA. Due to the COVID-19 outbreak, the Medical Device Control Division has agreed to facilitate all registration processes for establishments producing disposable medical masks.

Price Controls

As both alcohol-based hand sanitizer and disposable medical masks are currently in high demand, the Thai Central Committee on Prices of Goods and Services (CCP) has published a notification announcing price controls. For alcohol-based hand sanitizer, the manufacturer, importer, and distributor of the product must notify the CCP of the pricing details. In addition, the price may not be increased without receiving permission from the CCP. For domestically manufactured disposable medical masks, the retail price must not exceed THB 2.50 (approx. USD 0.08). However, the price of imported masks has not yet been fixed. The CCP has only required that the importer, distributor, and retailer not mark up the price more than 10%, 10%, or 23%, respectively. As for exports, the CCP has banned all unauthorized exportation of medical masks. Though they had previously directed exporters to seek permission only for shipments of 500 masks or more, this led some exporters to divide their shipments to circumvent the requirement. Therefore, according to the latest CPP notification, all exporters must first obtain approval from the CPP before exporting mask products, regardless of the amount to be exported. Meanwhile, the price of these products in the Thai market continues to rise as the fixed-price policy only applies to domestically manufactured disposable medical masks and because some traders do not obey the law when faced with high demand.
    In summary, the widespread concern about the COVID-19 pandemic has spurred the Thai government to ensure an adequate supply of masks and alcohol-based  hand sanitizer for the public. Their regulatory moves and relaxation of certain requirements have indeed eased  supply problems; on the other hand, vendors acting in bad faith have exploited legal loopholes, increasing the already substantial chaos and turmoil gripping society. For instance, there were reports of individuals hoarding large quantities of masks for resale in the black market and for illegal exportation. Moreover, some unscrupulous vendors recycled used masks and resold them as new ones. As a result, the government has ordered severe punishment for anyone who violates the law during this trying situation. It is thus imperative at this time that healthcare entrepreneurs understand and comply with the law governing the supply of products in need during the COVID-19 pandemic.

RELATED INSIGHTS​ 

May 27, 2025
On May 16, 2025, Vietnam’s Ministry of Health (MOH) issued Circular No. 12/2025/TT-BYT on registration of drugs and drug materials (Circular 12). Circular 12 will come into effect on July 1, 2025, replacing Circular No. 08/2022/TT-BYT (as amended), which provides the current regulations on drug registration, along with Circular No. 16/2023/TT-BYT on registration of drugs under toll manufacturing and technology transfer, and Circular No. 07/2017/TT promulgating the list of non-prescription drugs. Some of the key stipulations of Circular 12 are outlined below. Regulation of non-prescription drugs Circular 12 abolishes the detailed list of over-the-counter (OTC) drugs previously stipulated in Circular No. 07/2017/TT-BYT. Instead of relying on a fixed list for classification, Circular 12 introduces a new framework based on principles, criteria, and specific methods for determining the status of non-prescription/OTC drugs. This approach aims to enhance safety, ensure timely access, reflect actual usage and supply conditions, and align with international standards. Drugs that have already been approved will retain their classification (i.e., as prescription or non-prescription) throughout the validity of their marketing authorization (MA), and reclassification will be considered when the MA is renewed. If a change in classification is requested, the MA holder must submit a variation registration dossier to the Drug Administration of Vietnam (DAV). For drug registration dossiers currently under evaluation by the DAV, the classification will be assessed in accordance with the new provisions set out in Circular 12. Drug registration The new regulations under Circular 12 loosen the requirements on providing a Certificate of Pharmaceutical Product (CPP). For all drug registration cases, a single CPP will suffice, provided it is issued by the competent authority of the manufacturing country or by an authority from a country that is a member of the European Medicines Agency (EMA) or a Stringent Regulatory Authority (SRA), and confirms
May 15, 2025
Vietnam’s Ministry of Health (MOH) has published for public consultation a draft amendment of the Law on Donation, Recovery, and Transplantation of Human Tissues and Organs and Donation and Retrieval of Cadavers, a law which has been in effect since 2007. Among its changes, the draft amendment notably includes new provisions on stem cells, a hot-button topic with social, legal, and ethical ramifications extending beyond the medical field. There are currently no specific regulations on stem cells under Vietnamese law—only the MOH’s technical guidance—leaving many controversial issues unsettled. Key points related to stem cells that may impact the activities of researchers and institutions in Vietnam and abroad are highlighted below. Requirements for Stem Cells Under the draft amendment, stem cells are defined as cells naturally occurring in the body, having the ability to divide and differentiate into various types of cells. The draft amendment outlines conditions for stem cell donation, establishes requirements for medical facilities authorized to receive stem cell donations, and specifies the rights of stem cell donors. Under the draft amendment, it is prohibited to receive, screen, or produce stem cells at facilities that do not satisfy conditions. Establishment of Private Stem Cell Banks In addition to state-owned stem cell banks, the draft amendment also addresses independent stem cell banks established by private investors. In general, the stem cell banks (whether public or private) must obtain an operation license by meeting various conditions on personnel, equipment, facilities, and management systems to be further guided by the government. Notably, stem cell banks will have the right to cooperate with foreign entities in exchanging stem cells for treatment, education, and research purposes. Prohibition on Creating Embryos for Stem Cell Research or Therapy Considering the ethical concerns over the use and destruction of embryos, the draft amendment expressly prohibits the
May 2, 2025
Attorneys from Tilleke & Gibbins have updated the latest edition of Doing Business in Thailand, a Q&A-style guide from Thomson Reuters Practical Law that offers an overview of key legal considerations for companies operating in jurisdictions worldwide. The contribution outlines the country’s legal and regulatory framework for foreign investment and business operations and reflects the latest legislative developments. The chapter addresses the following core topics: Legal system: Structure of the courts and the codified nature of Thai law. Foreign investment: Business restrictions under the Foreign Business Act, sector-specific regulations, exchange control rules, and investment incentives. Business vehicles: Overview of partnerships, private and public limited companies, and other legal entities. Employment: Labor protections, employment contracts, foreign worker requirements, and termination procedures. Tax: Corporate and personal income tax, indirect taxes, and tax obligations for residents and non-residents. Intellectual property: Registration and enforcement of patents, trademarks, designs, and copyrights. Data protection: Key provisions of the Personal Data Protection Act and related compliance obligations. Competition law: Regulatory framework under the Trade Competition Act. Anti-bribery and corruption: Relevant legislation and enforcement mechanisms. E-commerce and digital business: Legal regime for online transactions and digital platforms. Marketing and advertising: Consumer protection laws and regulations affecting advertising and marketing practices. Product regulation and liability: Safety standards, liability regimes, and roles of enforcement authorities. Practical Law, a legal reference resource from Thomson Reuters, publishes a range of guides for hundreds of jurisdictions and practice areas. The insurance and reinsurance guide is a valuable resource for legal practitioners, covering numerous jurisdictions worldwide. To view the latest version of the guide, please visit the Practical Law website and enroll in the free Practical Law trial to gain full access.
March 7, 2025
On November 22, 2024, the Ministry of Health (MOH) in Laos issued Decision No. 3730/MOH, which regulates the management, processing, production, and use of biopharmaceutical products, genes, and stem cells. This decision came into force on January 18, 2025, 45 days after its publication in the Lao Official Gazette on December 4, 2024. This decision signifies Laos’ recognition and acceptance of biopharmaceutical products, genes, and stem cells for use in medical treatments and the beauty industry, and it aligns with the ongoing development of biomedical sciences in the country. Definitions The MOH’s decision defines biopharmaceuticals, gene therapy, and stem cells as follows: “Biopharmaceutical products” refers to a type of biological or drug product that is produced or synthesized from natural substances, objects, or chemicals. This group of products includes blood, blood components, allergens, cells or cellular components, gene therapies, tissues, protein-based medicines, drugs derived from living cells, and biologics, which can be produced from sugars, proteins, amino acids, or substances with complex characteristics derived from organic sources such as human, animal, and plant parts; yeast; and microorganisms. These products exclude vaccines and biosimilar products, which will be specified under separate regulations. “Gene therapy” refers to a treatment approach that applies the principle of arranging amino acids (which could involve DNA or RNA sent to the patient’s cells in the form of a drug with the purpose of treating a certain disease). “Stem cells” are defined in the decision as cells or immature cells that can be sourced from various organs in the They are characterized by being undifferentiated, having the potential for differentiation, and being self-renewing. Stem Cell Production The decision outlines comprehensive provisions for managing and using raw materials in stem cell production. Key points include: Production location standards: Ensuring facilities meet specific standards of the MOH. Personnel